Experimental data support a role for aldosterone in renal injury that is independent of renin and angiotensin II, and indicate that blocking the activity of this mineralocorticoid might ameliorate progression of chronic kidney disease. Lucia Del Vecchio and colleagues discuss these findings. The authors also review preliminary clinical trial data, which are consistent with a significant antiproteinuric effect of aldosterone antagonists such as spironolactone.
- Lucia Del Vecchio
- Mirella Procaccio
- Daniele Cusi
